Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(14 sites)
United States
MD Anderson Cancer Center, Houston, Texas China
Beijing cancer Hospital, Beijing, Beijing Municipality Nanfang Hospital, Guangzhou, Guangdong Hunan Cancer Hospital, Changsha West China Hospital, Sichuan University, Chengdu The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou Harbin Medical University Cancer Hospital, Harbin Shandong Cancer Hospital, Jinan Gansu Provincial Hospital, Lanzhou The Affiliated hospital of Qingdao University, Qingdao Fudan University Shanghai Cancer Center, Shanghai The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an First Affiliated Hospital of Zhengzhou University, Zhengzhou